2.47 USD
▼-0.07-2.76%
盘后 2.51 +1.62%
2026-09-15
市值
$104.86M
市盈率
—
EPS
-0.86
股息率
—
52 周区间
2.29 – 8.54
成交量
203.40K
Beta
0.56
目标价
19.00
52W 低 2.2952W 高 8.54
价格走势
公司简介
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...